In the nine years since the unexpected discovery of a second form of the estrogen receptor (ER), ERβ has been mentioned in about 2,800 literature citations. Such prolific research is testimony to interest in explaining its role in estrogen physiology as well as investigating its potential as a drug target. Our current understanding is that ERα, not ERβ is responsible for mediating the effects of estrogens in “classic” model systems such as the reproductive tract and skeleton. The role of ERβ is still being defined, but profiling of ERβ selective agonists in several animal models of human disease indicates these compounds may have utility as novel anti-inflammatory agents. The challenge for the future is to elucidate their mechanism of action and determine the clinical relevance of the impressive preclinical observations.
References
1.
CristofaroP.A., OpalS.M., PalardyS.M., ParejoN.A., JhungJ., KeithJ. C., and HarrisH. A. (In Press) WAY-202196, a selective estrogen receptor-β agonist, protects against death in experimental septic shockCritical Care Medicine
2.
FollettieM. T., PinardM., KeithJ. C.Jr., WangL., ChelskyD., HaywardC., KearneyP., ThibaultP., ParamithiotisE., DornerA. J., and HarrisH. A. (2006). Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-β selective agonist ERB-041Endocrinology147, 714–23.
3.
GreeneG. L., GilnaP., WaterfieldM., BakerA., HortY., and ShineJ. (1986). Sequence and expression of human estrogen receptor complementary DNAScience231, 1150–4.
4.
GreenS., WalterP., KumarV., KrustA., BornertJ. M., ArgosP., and ChambonP. (1986). Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-ANature320, 134–9.
5.
GrummerR., SchwarzerF., BainczykK., Hess-StumppH., RegidorP. A., SchindlerA. E., and WinterhagerE. (2001). Peritoneal endometriosis: validation of an in-vivo modelHum Reprod16, 1736–43.
6.
HarrisH. A., Bruner-TranK. L., ZhangX., OsteenK. G., and LyttleC. R. (2005). A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosisHum Reprod20, 936–41.
7.
HarrisH. A., KatzenellenbogenJ. A., and KatzenellenbogenB. S. (2002). Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligandEndocrinology143, 4172–7.
8.
HarrisH. A., AlbertL. M., LeathurbyY., MalamasM. S., MewshawR. E., MillerC. P., KharodeY. P., MarzolfJ., KommB. S., WinnekerR. C., FrailD. E., HendersonR. A., ZhuY., and KeithJ. C.Jr. (2003). Evaluation of an estrogen receptor-β agonist in animal models of human diseaseEndocrinology144, 4241–9.
9.
Hegele-HartungC., SiebelP., PetersO., KosemundD., MullerG., HillischA., WalterA., KraetzschmarJ., and FritzemeierK. H. (2004). Impact of isotype-selective estrogen receptor agonists on ovarian functionProc Natl Acad Sci U S A101, 5129–34.
10.
KuiperG. G., EnmarkE., Pelto-HuikkoM., NilssonS., and GustafssonJ. A. (1996). Cloning of a novel receptor expressed in rat prostate and ovaryProc Natl Acad Sci U S A93, 5925–30.
11.
LubahnD. B., MoyerJ. S., GoldingT. S., CouseJ. F., KorachK. S., and SmithiesO. (1993). Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor geneProc Natl Acad Sci U S A90, 11162–6.
12.
LundT. D., RovisT., ChungW. C., and HandaR. J. (2005). Novel actions of estrogen receptor-β on anxiety-related behaviorsEndocrinology146, 797–807.
13.
ManasE. S., UnwallaR. J., XuZ. B., MalamasM. S., MillerC. P., HarrisH. A., HsiaoC., AkopianT., HumW.T., MalakianK., WolfromS., BapatA., BhatR. A., StahlM. L., SomersW. S., and AlvarezJ. C. (2004). Structure-based design of estrogen receptor-β selective ligandsJ Am Chem Soc126, 15106–19.
14.
MewshawR. E., EdsallR. J.Jr., YangC., ManasE. S., XuZ. B., HendersonR. A., KeithJ. C.Jr., and HarrisH. A. (2005). ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivityJ Med Chem48, 3953–79.
15.
MeyersM. J., SunJ., CarlsonK. E., MarrinerG. A., KatzenellenbogenB. S., and KatzenellenbogenJ. A. (2001). Estrogen receptor-β potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analoguesJ Med Chem44, 4230–51.
16.
OpasE. E., GentileM. A., KimmelD. B., RodanG. A., and SchmidtA. (2006). Estrogenic control of thermoregulation in ERalphaKO and ERbetaKO miceMaturitas53, 210–6.
17.
StaufferS. R., ColettaC. J., TedescoR., NishiguchiG., CarlsonK., SunJ., KatzenellenbogenB. S., and KatzenellenbogenJ. A. (2000). Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-α-selective agonistsJ Med Chem43, 4934–47.
18.
VeenemanG. H. (2005). Non-steroidal subtype selective estrogensCurr Med Chem12, 1077–136.
19.
WalfA. A., and FryeC. A. (2005). ERbeta-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized ratsNeuropsychopharmacology30, 1598–609.
